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2H magnetic resonance spectroscopic imaging has been shown recently to be a 
viable technique for metabolic imaging in the clinic.  We show here that 2H MR 
spectroscopy and spectroscopic imaging measurements of [2,3-2H2]malate 
production from [2,3-2H2]fumarate can be used to detect tumor cell death in vivo via 
the production of labeled malate.   Production of [2,3-2H2]malate, following injection 
of [2,3-2H2]fumarate (1 g/kg) into tumor-bearing mice, was measured in a murine 
lymphoma (EL4) treated with etoposide, and in human breast (MDA-MB-231) and 
colorectal (Colo205) xenografts treated  with a TRAILR2 agonist, using surface-coil 
localized 2H MR spectroscopy at 7 T.  Malate production was also imaged in EL4 
tumors using a fast 2H chemical shift imaging sequence.  The malate/fumarate ratio 
increased from 0.016 ± 0.02 to 0.16 ± 0.14 in EL4 tumors 48 h after drug treatment 
(P=0.0024, n=3), and from 0.019 ± 0.03 to 0.25 ± 0.23 in MDA-MB-231 tumors (P = 
0.0001, n=5) and from 0.016 ± 0.04 to 0.28 ± 0.26 in Colo205 tumors (P = 0.0002, 
n=5) 24 h after drug treatment. These increases were correlated with increased 
levels of cell death measured in excised tumor sections obtained immediately after 
imaging.  2H MR measurements of [2,3-2H2]malate
 production from [2,3-2H2]fumarate 
provides a potentially less expensive and more sensitive method for detecting cell 
death in vivo than 13C MR measurements of hyperpolarized [1,4-13C2]fumarate 








There is an unmet clinical need for sensitive methods for detecting  cell death in vivo, 
for example in disease and following tumor treatment.  We show here that deuterium 
magnetic resonance measurements at 7 T of labeled malate production from injected 
2H-labelled fumarate provides a sensitive method for detecting tumor cell death in 
vivo following treatment.  Malate production was relatively slow in viable cells but 







Currently the response of solid tumors to treatment is assessed mainly on the basis 
of changes in tumor size (Response Evaluation Criteria in Solid Tumors (RECIST) 
(1).  However, changes in size may take weeks to appear after the initiation of 
treatment, and in some cases may not appear at all, for example in the case of 
treatments that inhibit tumor growth but do not result in tumor regression (2, 3). 
Changes in metabolism can give an earlier indication of treatment response, for 
example assessment of glycolytic activity using PET measurements of 2-[18F]-fluoro-
2-deoxy D-glucose uptake (FDG-PET).  PET Response Criteria in Solid Tumors 
(PERCIST) was introduced as a potentially more sensitive method of assessing 
treatment response when compared to assessment based on changes in tumor size 
alone (4), particularly with therapies that stabilize disease.  Imaging with 
hyperpolarized [1-13C]pyruvate, like FDG-PET, can also be used to detect drug 
target engagement as well as subsequent tumor cell death (5, 6). We have shown 
recently that imaging hyperpolarized [1-13C]pyruvate metabolism can be more 
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sensitive than FDG-PET in detecting reductions in glycolytic flux associated with 
tumor cell death post treatment (7).   
 
While metabolic imaging may indicate drug target engagement, and in some cases 
tumor cell death, there is a need for imaging methods that detect tumor cell death 
more directly post-treatment and that can give an indication of longer term treatment 
outcomes (8).  Fumarate is hydrated in the reaction catalyzed by the intracellular 
enzyme fumarase to produce malate. Previous 13C magnetic resonance 
spectroscopic imaging (MRSI) studies with hyperpolarized [1,4-13C2]fumarate in 
tumor models and in models of myocardial infarction and acute kidney necrosis (9-
16) have demonstrated that the production of labeled malate can be used to image 
cell death in vivo.  The increased production of malate was attributed to loss of the 
plasma membrane permeability barrier in necrotic cells and increased access of 
hyperpolarized [1,4-13C2]fumarate to fumarase. However, imaging with 
hyperpolarized 13C-labelled substrates is limited both by the transient nature of the 
hyperpolarization, which restricts its application to relatively fast metabolic 
processes, and the requirement for relatively large amounts of 13C-labeled 
compounds and access to clinical hyperpolarizers, which are expensive. The recent 
demonstration by De Feyter et al that 2H MRSI can be used to image the metabolism 
of 2H-labelled substrates in vivo, including in human subjects (17), has provided a 
potentially lower cost alternative for clinical metabolic imaging. The relatively low 
sensitivity of 2H detection is compensated by its very short T1, which means that 
signal can be acquired rapidly without saturation.  The main limitation is the narrow 
frequency range, which requires the use of relatively high magnetic field strengths.  
Nevertheless, by collecting a series of rapidly acquired images, the technique is 
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capable of generating quantitative images of metabolic flux (18). We show here that 
2H MRS and MRSI measurements of [2,3-2H2]fumarate conversion to 
2H-labeled 
malate can be used to detect tumor cell death in vivo and that this is potentially a 
more sensitive method for detecting cell death than 13C MRSI with either 
hyperpolarized [1-13C]pyruvate or [1,4-13C2]fumarate. 
  
Materials and Methods 
More detailed information is give in the Supplementary Information file. 
 
Cell culture 
Murine lymphoma EL4 and human colorectal adenocarcinoma Colo205 cells were 
cultured in RPMI medium (Life Technologies) supplemented with 2 mM L-glutamine 
and 10% fetal bovine serum (FBS) (Gibco/Thermo Fisher Scientific) and human 
triple negative breast cancer MDA-MB-231 cells in Dulbecco’s Modified Eagle 
Medium (DMEM) (Gibco) containing 10 % FBS.   
 
Tumor implantation 
EL4, MDA-MB-231 or Colo205 cells were injected subcutaneously at 5 x 106, 7 x 106 
and 10 x 106 cells respectively.  EL4 tumors were allowed to develop for 10 days 
before imaging, whereas Colo205 and MDA-MB-231 tumors were imaged after 14 
days and 35 days respectively. Animals bearing EL4 tumors were treated with 
etoposide (67 mg/kg of body weight, intraperitoneally), or solvent vehicle (saline) 48 
h before imaging.  Animals bearing MDA-MB-231 or Colo205 tumors were treated 
with MEDI3039 (19) (0.8 mg/kg of body weight; intravenously) or solvent vehicle 
(saline) 24 h before imaging. All animal experiments were carried out in compliance 
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with project and personal licenses issued by the Home Office, UK and approved by 
the Cancer Research UK, Cambridge Institute Animal Welfare and Ethical Review 
Body. 
 
Synthesis of disodium [2,3-2H2]fumarate and measurement of T1 
Three g of [2,3-2H2]fumaric acid (Sigma-Aldrich) were dissolved in 8 M NaOH and 
then freeze-dried. The 2H T1s of fumarate, HDO and of DMSO-d6 (3 mM) and 
formate-d (5 mM), which were used as chemical shift and intensity standards, were 
measured using an inversion recovery sequence at 147 ms, 199 ms, 719 ms and 
1.637 s respectively.   
 
2H MR spectroscopy measurements on media samples 
EL4 cells in suspension were treated with 15 μM etoposide and Colo205 and MDA-
MB-231 cells on plates with 10 pM MEDI3039 for 24 h. The cells were then washed 
in PBS, resuspended at 1 x 106  cells/ml in 10 ml culture medium, and 5 mM [2,3-
2H2]fumarate was added.  One ml samples were taken at the specified time points 
and 2H NMR spectra were acquired The amplitudes of the water, fumarate and 
malate resonances were normalized to the DMSO-d6 peak, after correction for the 
slight saturation of the DMSO-d6 resonance, in order to calculate concentrations (17, 
18).  Absolute concentrations were obtained by correcting for the numbers of 
deuterons per molecule. 
 
MR spectroscopy and spectroscopic imaging in vivo 
Experiments were performed at 7 T (Agilent, Palo Alto, CA) using a 72 mm diameter 
birdcage volume coil for 1H transmit and receive (Rapid Biomedical GMBH, Rimpar, 
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Germany) and a home-built 10 mm diameter single-loop surface coil, located over 
the tumor, for 2H transmit and receive. The tumors were localized in axial 1H images 
acquired with a fast spin echo (FSE) pulse sequence. Serial 2H spectra were 
acquired using a pulse-acquire sequence with a 2 ms BIR4 (20) adiabatic excitation 
pulse, with nominal flip angle of 67º, a TR of 140 ms and a spoiler gradient on the Z-
axis to dephase any residual transverse magnetization.  Thirteen, 5 minute spectra 
were acquired over 65 minutes.  Localization of signal to the tumors was achieved by 
the excitation profile of the surface coil and confirmed by chemical shift images, 
which showed that signal was largely confined to the tumors.  After peak fitting, the 
intensity of the HDO peak at the first time point was assumed to correspond to the 
natural abundance of 2H in HDO, which has been estimated to be 10.12 mM in 
tissue (17, 18). The HDO signal provides an internal reference, which was used to 
estimate the concentration of deuterated fumarate.  The signals were corrected for 
saturation (15%) by assuming that the T1s in vivo were similar to those measured in 
vitro at 14.1 T and correcting for the number of 2H nuclei in [2,3-2H2]fumarate.  The 
concentration of malate was estimated from the intensity of the upfield resonance 
and assuming that it has a similar T1 to the fumarate resonance. The downfield 
resonance and the HDO peak overlap in vivo, which results in a slight overestimation 
of the labelled water concentration at later time points. 3D chemical shift images 
(CSI) were acquired as described in (18). Disodium [2,3-2H2]fumarate was dissolved 
in water at a concentration of 312.5 mM and infused via a tail vein catheter.  The 
infusion started 5 min after the start of spectral or image acquisition and resulted in 1 
g/kg body weight of [2,3-2H2] disodium fumarate infused over a period of 20 min. 
 
MR spectroscopy of blood extracts 
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EL4 tumor-bearing mice (n = 6) were injected with 1 g/kg [2,3-2H2]fumarate under 
isoflurane anesthesia. Blood was taken via cardiac puncture at 20 (n=3) and 70 
(n=3) min after fumarate injection.  Blood from two more mice was taken without 
prior injection of fumarate. The blood was vortexed in ice-cold 2M perchloric acid 
(PCA) for 30 s, centrifuged at 13,000 g at 4 °C for 15 min and then neutralized with 
ice-cold 2M KOH.  The neutralized extract was then centrifuged for 10 min at 13,000 
g and 200 µl of the supernatant added to 300 µl H2O and a formate-d standard 
added to a final concentration of 4 mM. 2H NMR spectra were acquired using the 
same acquisition parameters as used for the media samples, but with a TR of 3 s.  
Concentrations were calculated by comparison of the signal intensities with that of 
the formate-d standard, after correction for slight signal saturation in the latter.  A 
standard for proton NMR measurements (3-(trimethylsilyl)-2,2,3,3-
tetradeuteropropionic acid) was then added to give a final concentration of 1 mM, 
together with 50 µl 2H2O, and 
1H spectra were acquired with water pre-saturation 
and a flip angle of 90º into 16384 data points, with a spectral width of 7788 Hz and a 
repetition time of 8 s. 
 
MR spectroscopy of tissue extracts 
EL4 tumor-bearing mice were injected with 1 g/kg [2,3-2H2]fumarate (n=3) or PBS 
(n=3)  under isoflurane anesthesia and after 20 min the animals were killed by 
cervical dislocation and tumor, kidney, liver, and muscle tissue were freeze-clamped 
in liquid nitrogen-cooled tongs. For measurements on heart muscle, non-tumor 
bearing C57BL/6J mice (n=8) were either injected with 1 g/kg [2,3-2H2]fumarate or 
PBS (n=3) under isoflurane anesthesia and after 20 (n=3) and 60 min (n = 2) the 
animals were killed by cervical dislocation. The chest cavity was opened to expose 
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the heart, the descending aorta, inferior vena cava, and pulmonary trunk were cut, 
and the heart immediately flushed anterograde with ice-cold PBS by inserting a 
cannula into the apex of the right ventricle to inhibit contraction and to flush blood 
from the chambers. Remaining blood was aspirated from the ventricles and the heart 
submerged in a dish filled with ice-cold oxygenated Krebs-Henseleit buffer before the 
tissue was freeze-clamped in liquid nitrogen-cooled tongs.  The frozen samples were 
homogenized in ice-cold 2M PCA using a Precellys Cryolys Evolution tissue 
homogenizer (Bertin Instruments) and neutralized with 2M KOH. After centrifugation 
for 15 min at 13,000 g, 200 µl of the supernatant was mixed with 300 µl of H2O and a 
formate-d standard added to a final concentration of 4 mM. 2H NMR spectra were 
acquired using the same acquisition parameters as used for the blood samples. 
Following the 2H NMR measurements, a standard for proton NMR measurements, 3-
(trimethylsilyl)-2,2,3,3-tetradeuteropropionic acid was added at a final concentration 
of 1 mM, together with  50 µl of 2H2O, and 
1H spectra were acquired, as for the blood 
samples.  
 
2H MR spectroscopy of erythrocyte suspensions 
Erythrocytes were diluted to a haematocrit of ~40% in Krebs-Henseleit buffer (NaCl 
118.5; NaHCO3 25.0; KCl 4.7; KH2PO4 1.2; MgSO4 1.2; glucose 11; CaCl2 2.4; 
mmol/L, pH 7.4) gassed with 95% O2 / 5% CO2. 
2H NMR spectra were acquired at 
310 K following the addition of 8 mM [2,3-2H2]fumarate and 5 mM formate-d6.  
Spectra were acquired using a 90° pulse, a repetition time of 2 s and were the sum 
of 150 transients. 
 
Dynamic contrast-enhanced MRI 
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EL4, MDA-MB-231 and Colo205 tumor-bearing animals (n = 3 per group) underwent 
dynamic contrast-enhanced (DCE)-MRI before and either 48 (EL4) or 24 (MDA-MB-
231 and Colo205) hours after treatment with etoposide (EL4) or MEDI3039 (MDA-
MB-231 and Colo205).  Images were acquired at 9.4 T using a 40 mm diameter 1H 
volume coil. Baseline T1 measurements were made using an inversion recovery-fast 
spin echo sequence.  A series of 500 spoiled gradient echo images (2 averages, 5 
seconds per set of 3 images) were acquired.  Dotarem, at 200 moles/kg (Gadoteric 
acid, Guerbet), was injected via a tail vein after the 10th image. Signals from the 
image series were converted, on a pixel-by-pixel basis, to a contrast-agent 




Freeze-clamped tumor samples were homogenized in 10 L/mg RIPA buffer 
(ThermoFisher Scientific) containing cOmplete mini EDTA-free protease inhibitor 
(Sigma Aldrich). Membranes were probed with a rabbit polyclonal IgG fumarase 
antibody (ThermoFisher) and a mouse monoclonal GAPDH antibody (Abcam) and 
detected using IRDye 800CW Goat anti-Rabbit IgG (LI-COR) and IRDye 680LT Goat 
anti-Mouse IgG antibodies (LI-COR). 
 
Measurements of fumarase activity and ATP concentration in tissue extracts 
Fumarase activity and ATP concentrations were determined using colorimetric 
(ab196992, Abcam) and fluorometric kits (ab83355, Abcam), respectively.   At 48 h 
after treatment with etoposide (EL4), and 24 h after treatment with MEDI3039 (MDA-
MB-231 and Colo205) or drug vehicle, tumors were freeze-clamped and either 
homogenized in ice-cold 4 M PCA (ATP assay) or in assay buffer (fumarase assay) 
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using a Precellys 24 homogenizer (Stretton Scientific). The ATP extracts were 
neutralized with 8 M KOH.  Fumarase activity was assayed spectrophotometrically 
by measuring the conversion of malate to fumarate from the increase in absorbance 
at 450 nm, according to the manufacturer’s instructions. ATP concentration was 
determined fluorometrically (Ex/Em = 535/587 nm), again according to the 
manufacturer’s instructions. Both measurements were made using a PHERAstar FS 
microplate reader (BMG Labtech). 
 
Histology and immunohistochemistry 
Sections of formalin-fixed paraffin-embedded tumors (10 m) were stained with 
hematoxylin and eosin and with a rabbit monoclonal anti-CC3 antibody (Cell 
Signaling Technology) and a donkey anti-rabbit secondary biotinylated antibody 
(Jackson ImmunoResearch Laboratories).  Sections were also stained using TdT-
mediated dUTP Nick- End Labeling (TUNEL) (PromegaBenelux BV). Slides were 




Statistical and graphical analyses was performed using Prism v8 (GraphPad). Data 
are shown as mean ± SD, unless stated otherwise. Analysis of variance was used 
for multiple comparisons of groups to determine significance. A paired or unpaired 
Student t test was used for single-parameter comparisons. P values are summarized 
in figure tables as: * P = 0.01 – 0.05; ** P = 0.001 – 0.01; *** P = 0.0001 – 0.001; **** 




Deuterated fumarate metabolism detects tumor cell death in vitro 
Cultured murine lymphoma cells (EL4) (Figure 1) were treated with 15 M etoposide  
or drug vehicle (control)  for 24 h.   Cell viability was 90 ± 3% prior to treatment and 9 
± 4% at 24 hours post-etoposide treatment. Five mM [2,3-2H2]fumarate was added to 
the cell suspensions and samples taken for 2H NMR measurements of the 
deuterated fumarate, malate and water concentrations. As early as one minute after 
[2,3-2H2]fumarate addition, etoposide-treated cells showed increased malate 
production (Figure 1A,B). The deuterium-labeled malate concentration was 1.3 ± 0.4 
mM in drug-treated cell suspensions as compared to 0.17 ± 0.04 mM in controls (P < 
0.0001, n=3 per group).  The labeled malate production rate was significantly higher 
(P = 0.0004) in the etoposide-treated group (34.1 ± 1.8 fmol/min/cell) compared to 
controls (12.9 ± 2.7 fmol/min/cell) (Fig. 1G).  Similar results were obtained in 
colorectal (Colo205) (Fig. 1H-J) and triple negative breast cancer (MDA-MB-231) 
cells (Fig. 1K-M).  The rates of malate production post-treatment were higher in 
Colo205 cells (6.1 ± 0.2 fmol/min/cell) (Fig. 1J) and MDA-MB-231 cells (9.1 ± 0.7 
fmol/min/cell) (Fig. 1M) compared to untreated controls (Colo205, 2.1 ± 0.6 
fmol/min/cell; MDA-MB-231, 2.2 ± 0.4 fmol/min/cell).   These rates were much lower 
than those observed in treated EL4 cells, however there was much less cell death, 
with the viabilities of these two cell lines post treatment being much higher (Colo205, 
56 ± 2.4%, MDA-MB-231, 55 ± 4.1%) than in EL4 cells (9 ± 4% ).   The rates of 
water labeling, which can be explained by TCA cycle activity (17, 18, 22, 23), were 
not significantly affected by treatment.  The rate in untreated EL4 cells was 30.1 ± 
2.4 fmol/min/cell, in MDA-MB-231 cells 20.3 ± 4.9 fmol/min/cell and in Colo205 cells 
16.7 ± 5.8 fmol/min/cell, whereas in treated cells the corresponding rates were 35.6 
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± 1.2, 18.7 ± 4.9 and 19.3 ± 2.4 fmol/min/cell respectively, indicating that there was 
retention in the  necrotic cells of the activities of those enzymes responsible for 
exchange of fumarate deuterons with water.  Moreover, these rates were similar to 
the rates of fumarate utilization, which in untreated EL4 cells was 31.9 ± 3.8 
fmol/min/cell, in MDA-MB-231 cells 10.1 ±  5.1 fmol/min/cell and in Colo205 cells 
17.6 ± 3.1 fmol/min/cell  and in the treated cells 38.9 ± 2.4, 12.3 ± 3.9 and 20.7 ± 6.9 
fmol/min/cell respectively.   
 
Deuterated fumarate metabolism detects tumor cell death in vivo 
Deuterium-labeled fumarate, malate and water concentrations were monitored in 
EL4, MDA-MB-231 and Colo205 tumors using localized 2H spectroscopy 
measurements following intravenous injection of 1 g/kg [2,3-2H2]-disodium fumarate 
(Figure 2). In all three implanted tumor models there was a significant increase in 
labeled malate concentration following drug treatment, which in the EL4 tumors was 
confirmed by measurements of the concentrations in freeze-clamped tumor extracts 
(Table 1).   In untreated tumors the concentration of [2,3-2H2]malate, determined by 
2H NMR, was only 10% of the unlabeled concentration, determined by 1H NMR, 
whereas in treated tumors the total malate concentration increased ~7x, of which 
~30% was deuterium labeled (Table 1). In both the untreated and treated tumors the 
fumarate was  ~50% labeled, indicating that there had been substantial solvent 
exchange of fumarate deuterons. The tumor malate/fumarate and malate/HDO 
signal ratios measured in vivo at 48 h (EL4) or 24 h (MDA-MB-231 and Colo205) 
after treatment are shown in Figure 3.  
 
The labeled malate concentration in etoposide-treated EL4 tumors (Figure 2 and 
Table 1) was ~4x the labeled malate concentration in blood (Table 2).  Moreover, the 
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labeled malate concentration in blood increased markedly posttreatment, consistent 
with the treated tumor being the major source of labeled blood malate.  Labeled 
malate was undetectable in liver and muscle but present in kidney at much higher 
concentration than in blood, both before and after treatment.  The increase in malate 
concentration in the kidney post treatment was comparable with the increase in the 
blood concentration.  The labeled fumarate concentration in the kidney pretreatment 
was similar to the blood concentration and approximately 2x that in the tumor and 5x 
that in the liver.  There were only very low concentrations of labeled fumarate in 
skeletal muscle.  Heart muscle takes up fumarate rapidly (24) and we observed 
labelled malate concentrations in this tissue that exceeded the blood concentration in 
untreated animals (Tables 1 & 2).  The labelled water concentration in heart muscle 
was similar to that in the blood pool.  Erythrocytes will also take up fumarate and 
produce malate on the time scale of the  experiments shown here (25).  Incubation of 
erythrocytes with  [2,3-2H2]fumarate produced concentrations of labelled malate 
comparable to those observed in the heart.  However, there was no increase in 
water labelling (Table 3), reflecting the low levels of TCA cycle enzymes in these 
cells (26). 
 
The tumor fumarate signal in the EL4 and MDA-MB-231 tumor models increased 
significantly following drug treatment (Figure 2A-D), implying that there was 
increased perfusion since the blood fumarate concentration did not change 
significantly following etoposide treatment (Table 2). To confirm changes in tumor 
perfusion, dynamic contrast enhanced MRI measurements were performed in EL4, 
MDA-MB-231 and Colo205 tumor-bearing mice. 
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DCE-MRI showed an increase in perfusion of EL4 and MDA-MB-231 tumors 
after treatment 
In separate cohorts of MDA-MB-231 (n=3) EL4 (n=3) and Colo205 (n=3) tumor-
bearing mice, DCE-MRI was used to assess tumor perfusion following drug 
treatment (Figure S1). Tumor gadolinium (Gd3+) concentrations pre- (0.25  0.02 
mM) and post-treatment (0.27  0.016 mM) showed no difference (P = 0.9953) in the 
Colo205 tumor model (Fig.4B), but were increased slightly by treatment in MDA-MB-
231 and EL4 tumor-bearing mice (Fig. 4D,F), increasing from 0.19  0.05 to 0.39  
0.09 mM (P = 0.0021) and 0.18  0.01 to 0.59  0.08 (P = 0.0001), respectively at 
approximately 10 minutes after intravenous injection of the contrast agent. 
 
Fumarase activity is decreased in cells and tumors by drug treatment 
Increased conversion of fumarate to malate has been attributed to compromised 
plasma membrane integrity in necrotic cells and consequently increased access of 
fumarate to the enzyme (9). To confirm this, we measured fumarase activity in drug-
treated cells in culture and in drug-treated tumors in vivo (Figure 4).  Enzyme activity 
was decreased in cells, and enzyme activity and protein levels were decreased in 
tumors, by drug treatment, confirming loss of plasma membrane integrity and 
leakage of the enzyme from the cell (9, 15).  
 
Confirmation of cell death in drug-treated tumors 
Cell death in drug-treated tumors was confirmed by measuring tumor size and ATP 
concentrations (Figure 5) and by histological assessment of the levels of cleaved 
capase 3 (CC3) and DNA damage (TUNEL) (Figure 6).  Although there was no 
significant decrease in the size of MDA-MB-231 and Colo205 tumors after 
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MEDI3039 treatment, there were nevertheless significant decreases in tumor ATP 
content and increases in CC3 and TUNEL staining, as we have observed previously 
in these tumor models following MEDI3039 treatment (7).  EL4 tumors showed a 
significant decrease in volume, from 0.7 ± 0.3 cm3 to 0.5 ± 0.1 cm3 at 48 h after 
etoposide treatment, and increases in CC3 and TUNEL staining. 
 
 
2H imaging of cell death using [2,3-2H2]fumarate 
A fast, dynamic 3D chemical shift imaging sequence was used to capture spatial 
information about the conversion of [2,3-2H2]fumarate to [2,3-
2H2]malate in implanted 
EL4 tumors in vivo following a bolus injection of labelled fumarate (1g/kg) into tumor-
bearing mice, both pre- and post-treatment (Figure 7). No malate signal was 
detected pre-treatment whereas significant malate production was observed 48 h 
after etoposide treatment. The signal was localized to the tumor area. The fumarate 
concentration also increased in the tumor post-treatment in agreement with the DCE 




13C MR spectroscopy and spectroscopic imaging of [1,4-13C2]malate production from 
hyperpolarized [1,4-13C2]fumarate has been used previously to detect early evidence 
of tumor cell death in EL4 tumors following treatment with etoposide (9) and in MDA-
MB-231 tumors following treatment with doxorubicin (10).   Production of labelled 
malate by necrotic cells has been attributed to a compromised plasma membrane 
permeability barrier allowing fumarate to rapidly gain access to cell fumarase with 
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consequent conversion to malate within the short lifetime of the 13C spin polarization, 
thus providing a positive marker of tumor cell necrosis.  We have shown here, using 
deuterium labelled fumarate, that the limited lifetime of the 13C spin polarization, 
which is of the order of 1 – 2 minutes  in vivo (27, 28), is not a prerequisite for an 
effective cell death measurement using labeled fumarate.  Untreated tumors had 
only low levels of [2,3-2H2]malate at 60 minutes after injection of [2,3-
2H2]fumarate, 
whereas in treated tumors elevated levels of [2,3-2H2]malate were detected within 15 
minutes.  Increased malate production in dead or dying cells cannot be explained by 
increased fumarase activity.  As was observed previously in studies with 
hyperpolarized [1,4-13C2]fumarate (9), enzyme activity decreased in drug-treated 
cells and tumors reflecting leakage of the enzyme from necrotic cells into the cell 
culture medium and tumor  interstitial space.  Increased malate production can also 
not be explained by increased delivery of labelled fumarate to the tumor post 
treatment.  Although  the EL4 and MDA-MB-231 tumors both showed significantly 
higher levels of [2,3-2H]fumarate post treatment, which DCE-MRI measurements 
showed was due to increased perfusion, this is unlikely to be responsible for the 
increased [2,3-2H2]malate signal post treatment since  the fumarate concentration in 
these tumors, both pre- and post-treatment, was in considerable excess of the Km of 
fumarase for fumarate, which has  been measured at 5 M (29). Moreover, Colo205 
tumors showed a similar increase in the levels of labelled malate post-treatment with 
no change in tumor perfusion, as assessed from the concentrations of [2,3-
2H2]fumarate and gadolinium contrast agent.  Furthermore, detecting cell death 
through an increase in the malate/fumarate signal ratio corrects for the effects of any 
changes in perfusion since the fumarate signal provides a measure of this. 
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While fumarate was taken up by viable cells, as evidenced by water labeling 
observed in the cell experiments, there was no subsequent accumulation of labeled 
malate, which we only observed in drug-treated cells and tumors.  Deuterons can be 
lost from [2,3-2H2]fumarate in the sequential reactions catalyzed by fumarase and 
malate dehydrogenase and subsequent keto-enol tautomerization of the 
oxaloacetate produced (30).  The similarity between the rate of fumarate 
consumption and water labelling in all three cell lines suggests that fumarate is taken 
up by viable cells and metabolized to malate and subsequently to oxaloacetate.  The 
absence of a significant increase in the rate of water labelling in Colo205 and MDA-
MB-231 cells following drug treatment, when >40% of the cells had become necrotic, 
suggests that in these cells the rate is limited by malate dehydrogenase activity and 
the rate of oxaloacetate tautomerization.  The rates of fumarate utilization increased 
in all three cell lines following treatment, consistent with the proposal that the 
increase in malate labeling is due to increased access of fumarate to fumarase in 
necrotic cells.  However, there was no concordance between the increase in the 
rates of fumarate utilization and malate labeling post-treatment across the three cell 
lines (7 versus 21 fmols/min/cell respectively in EL4 cells, 3 versus 4 fmols/min/cell 
in Colo205 cells and 2 versus 7 fmols/min/cell in MDA-MB-231 cells), suggesting that 
the observation of increased malate labeling may also be due to an increase in the 
steady state level of malate in drug-treated cells resulting from reduced  
consumption in the TCA cycle.  2H and 1H NMR measurements on EL4 tumor 
extracts showed a large increase in the concentrations of labeled and unlabeled 
malate post-treatment.  In untreated tumors only ~10% of the malate was deuterium 
labeled, which is likely due to production of malate from other carbon sources and 
also exchange of deuterium label in malate with solvent water in the reversible 
 19 
reaction catalyzed by malate dehydrogenase and subsequent keto-enol 
tautomerization of oxaloacetate.  Following etoposide treatment, the total malate 
concentration increased  7x, of which 30% was deuterium labeled.  Only ~50% of the 
fumarate in the tumors was  deuterium labeled, showing that there had been 
substantial solvent exchange in the tumor and other body tissues. 
 
Measurements in tissue extracts showed high levels of labelled fumarate in the 
kidneys (11 mols/g), presumably reflecting rapid renal excretion, as we have 
observed previously with hyperpolarized [1,4-13C2]fumarate (15), with lower levels in 
the tumor and lower levels still in the liver and heart (Table 1).  Labeled fumarate in 
the liver and heart muscle can be explained, at least in part, by labeled fumarate 
present in the blood pool.  With a blood [2,3-2H2]fumarate concentration of 12 mM at 
20 min after injection (Table 2), and using blood volumes in mouse liver and kidney 
of ~0.2 mL/g tissue (31), and accessible volumes (vascular plus interstitial) in liver 
and heart muscle of ~0.2 mL/g (32) gives a calculated concentration of labelled 
fumarate in the liver, kidney and heart muscle blood pools of ~2.4 mols/g tissue.  
This is similar to the measured tissue concentration of 2.1 mols/g in liver, although 
above that measured in heart, which was 1.2 mols/g.  The evidence that fumarate 
is largely present in the liver blood pool and not in the liver cells is further supported 
by the absence of detectable [2,3-2H2]malate in liver. The highest malate 
concentration in the blood would contribute only ~0.1 mols/g liver and was at the 
limit of detection in these 2H NMR measurements on liver extracts (Table 1).  
However, the labelled malate concentration in heart muscle was 0.3 mols/g, 10x 
that in the blood and indicating substantial uptake and metabolism of  fumarate in 
heart muscle, as has been observed previously (24).  This may explain why the 
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fumarate concentration in the heart was lower than that expected based on the 
concentration in the blood pool.  Fumarate uptake and metabolism in the heart may 
also have contributed to the observed water labeling in this tissue.  However, since 
the labeled water concentration was similar to that in the blood we cannot distinguish 
between labeled water generated in the heart and that washed in from other tissues.  
The labelled malate concentration in the kidney at 20 min after labelled fumarate 
injection (0.6 mols/g) was much higher than can be accounted for by the [2,3-
2H2]malate concentration in the blood (0.03 mM).  Some of this labelled malate may 
have been produced in the kidney but some may have been produced elsewhere in 
the body and was undergoing excretion via the kidneys.  In etoposide-treated EL4 
tumor-bearing mice the kidney malate concentration more than doubled to 1.3 
mols/g.  Although the blood concentration also increased, to 0.5 mM, again the 
blood pool can make only a very small contribution to the total kidney malate 
concentration.  Some of this malate is presumably malate that has washed out of the 
treated tumor, where the labelled malate concentration increased from 0.08 mols/g 
prior to treatment to 1.8 mols/g post-treatment, at 20 minutes after injection of [2,3-
2H2]fumarate.  Importantly the malate concentration in the tumor at this time point 
was ~4x higher than the blood concentration, demonstrating that the malate had 
been produced by cell death in the tumor rather than being washed in from 
elsewhere in the body. 
 
The production of malate from fumarate makes fumarate a positive contrast agent for 
detecting cell death and in principle should be more sensitive for detecting cell death 
than imaging techniques that rely on a decrease in signal, for example a decrease in 
tumor lactate labelling in animals injected with hyperpolarized [1-13C]pyruvate (5, 7).  
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In the same Colo205 and MDA-MB-231 tumor models that were used here we have 
shown previously that treatment with MEDI3039 resulted in a decrease in lactate 
labelling from hyperpolarized [1-13C]pyruvate (expressed as the 13C lactate/pyruvate 
signal ratio) of 42.2 ± 15.9% and 36.3 ± 18.6% in Colo205 and MDA-MB-231 tumors 
respectively (7). There was an increase in TUNEL staining in the Colo205 tumors, 
from 8.0 ± 6.7% to 19.4 ± 6.3% and in the MDA-MB-231 tumors, from 6.6 ± 2.0% to 
21.1 ± 6.1%.   Expressing the percentage decrease in lactate labelling as a ratio of 
the increase in the percentage of cell death gives values of 3.7 and 2.5 for Colo205 
and MDA-MB-231 tumors respectively.  In the study presented here, MEDI3039 
treatment resulted in an increase in the [2,3-2H2]malate/[2,3-
2H2]fumarate signal ratio 
from 0.016 ± 0.04 to 0.28 ± 0.26 in Colo205 tumors, a 1650 % increase, and an 
increase from 0.019 ± 0.03 to 0.25 ± 0.23 in MDA-MB-231 tumors, an increase of 
1216%.  TUNEL staining increased from 6.3 ± 2.3% to 77.6 ± 5.6% in Colo205 
tumors and from 5.0 ± 1.7% to 56.4 ± 3.9% in MDA-MB-231 tumors.  Expressing the 
percentage increase in malate labelling as a ratio of the increase in the percentage 
of cell death gives values of 23 and 24 for Colo205 and MDA-MB-231 tumors 
respectively.  Therefore, monitoring malate production from labelled fumarate is 
indeed a more sensitive method for detecting cell death than monitoring the 
decrease in lactate labelling from hyperpolarized [1-13C]pyruvate.  This assessment 
of sensitivity, however, does not take into account  the much lower signal-to-noise 
ratio (SNR) in the 2H spectra, which also has a  large effect on our estimate of the 
sensitivity of the deuterated fumarate experiment for detecting cell death given the 
very low intensity of the malate 2H signal in the untreated tumors.  The SNRs of the 
most intense malate peak in the 2H spectra of treated Colo205 and MDA-MB-231 
tumors were 1.70.6 and 2.30.9 respectively whereas the lactate SNRs in the 13C 
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spectra of these tumors published previously were 44±7 (7) and 46±8 respectively 
(10).  The differences in SNR between the 2H and 13C experiments will also depend 
on coil configuration and performance. 
 
We have shown previously that detecting cell death with hyperpolarized [1,4-
13C]fumarate is more effective than diffusion-weighted 1H MRI at detecting low levels 
of diffuse necrosis (11).   Treatment of EL4 tumors with an anti-vascular drug that 
resulted in small areas of necrosis at 6 hours after treatment  resulted in a significant 
increase in labeled malate production with no change in the apparent diffusion 
coefficient (ADC) of tissue water in a diffusion-weighted imaging experiment.  This 
was consistent with a previous study, which showed in tumors with small and diffuse 
regions of necrosis that there can be no change in ADC, even with necrotic fractions 
of up to 40% (33).  Malate detection effectively integrates cell death over the whole 
imaging voxel, since it is a positive contrast agent, whereas with small and diffuse 
regions of necrosis in the image voxel, detection of cell death using diffusion-
weighted MRI involves measuring relatively small increases in the water ADC.  
Assessing cell death in vivo using [2,3-2H2]fumarate is simpler than with 
hyperpolarized [1,4-13C]fumarate since the method does not require a 
hyperpolarizer, and as a result is also less expensive to implement.  However, it 
does require much higher concentrations of labelled fumarate;  0.4 mL of 312 mM 
[2,3-2H2]fumarate was used here as compared to 0.2 mL of 20 mM hyperpolarized 
[1,4-13C]fumarate used previously (9).  Despite the higher fumarate concentration, 
the SNR of the most intense [2,3-2H]malate signal was only 2.90.2 in the spectra of 
etoposide-treated EL4 tumors, which were the sum of 2,142 transients acquired over 
5 minutes using a 67º pulse and a repetition time of 0.14 s and 4.50.5 in the sum of 
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the 13 spectra acquired over 65 minutes.  Signal was acquired from the sensitive 
volume of the surface coil, which imaging experiments showed included mainly 
tumor tissue.   Contrast this with 13C spectroscopy measurements of hyperpolarized 
[1,4-13C]fumarate metabolism in etoposide-treated EL4 tumors where the malate 
SNR in spectra, which were the sum of 60 transients acquired over 3 minutes using 
a 10° pulse, a repetition time 3 s, and a slice thickness of 5 mm, was 17 (9).  
Increasing the concentration of [2,3-2H2]fumarate further was not possible as this 
started to affect breathing and heart rates, which may have been a consequence of 
the sodium ion present in the preparation.  The LD50 for i.v. sodium chloride in mice 
is 645 mg/kg, which is approximately 2.8 osmol/L; we injected 1 osmol/L disodium 
fumarate.  However, 2H MRS measurements of [2,3-2H]malate production from [2,3-
2H]fumarate  appear to be an intrinsically more sensitive method for detecting cell 
death than 13C MRS measurements of [1,4-13C]malate production from 
hyperpolarized [1,4-13C]fumarate. In EL4 tumor-bearing mice injected with 
hyperpolarized [1,4-13C]fumarate the rate constant describing labelled malate 
production in the tumor increased by a factor of 2.4 following etoposide treatment 
and the ratio of the areas under the malate and fumarate labelling curves increased 
by a factor of 1.6, where this was the result of an increase in tumor cell necrosis from 
~5% to ~30% (9).   Whereas in this study, in EL4 tumor-bearing mice injected with 
[2,3-2H2]fumarate, the ratio of the areas under the malate and fumarate labelling 
curves increased by a factor of 10,  increasing from 0.02 ± 0.02 to 0.16 ± 0.14 
(P=0.0024, n=3) following etoposide treatment, with the estimated levels of tumor 
cell necrosis increasing from 15 ± 5% to 59 ± 6%.   This greater sensitivity of the 2H 
experiment for detecting cell death can be explained by the extended period over 
which the accumulation of labeled malate is measured, 65 mins, as compared to just 
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3 min in the case of the  hyperpolarized 13C experiment, which is limited by the short 
lifetime of the 13C hyperpolarization. 
 
The chemical shift separation of the fumarate, water and  malate resonances and the 
concentrations of fumarate and malate observed in the tumors suggest that this 
technique for detecting tumor cell death post-treatment could translate to the clinic.  
De Feyter et al (17) observed partially resolved resonances from water and glucose 
at 4.8 and 3.8 ppm respectively, and resolved  resonances from Glx and lactate at 
2.4 and 1.4 ppm respectively in the human brain at 4 T.  Here, at 7 T, we observed 
partially resolved resonances from fumarate and water at 6.5 and 4.8 ppm 
respectively and a resolved resonance from malate at 2.4 ppm.  Since the fumarate 
and malate resonances show larger chemical shift differences from their immediately 
adjacent resonances than the water, glucose, Glx and lactate resonances, and since 
the resolution of the 2H spectra scales linearly with magnetic field (34), then we 
would expect the fumarate and malate resonances to be resolved from each other 
and from the water resonance at 3 T, a field more widely used in the clinic.  De 
Feyter et al detected glucose and Glx at concentrations of up to 1.5 and  2 mM 
respectively in 20 × 20 × 20 mm3 voxels in the normal human brain at 4 T.  Here we 
detected fumarate and malate concentrations of around 5 mM.  The expected 
decrease in sensitivity in going from 4 to 3 T is ~40% (34) and therefore we expect to 
be able to detect fumarate and malate at 3 T, even if the fumarate dose has to be 
decreased for human studies. 
 
In conclusion, this study has demonstrated that 2H spectroscopy and spectroscopic 
imaging of [2,3-2H2]fumarate metabolism can be used to detect tumor cell death 
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post-treatment, before there are detectable changes in tumor size. Translation of this 
technique to the clinic could offer a new approach to detecting early tumor responses 
to therapy and potentially to detect cell death in other conditions, such as acute 
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  Control Etoposide-treated 



















Tumor  5.23  0.63 0.08  0.02 6.82  0.84 1.81  0.53 
Kidney  11.03  1.01 0.58  0.03 7.20  0.82 1.27  0.39 
Liver  2.06  0.25 n.d. 2.14  0.52 n.d. 
Muscle  0.017  0.011 n.d. 0.050  0.016 n.d. 
Heart      
0 18.80±0.50     
20 min 20.48±0.69 1.17±0.25 0.27±0.18   
60 min 21,21±0.78 0.87±0.024 0.31±0.09   
      
  Concentrations of protonated species 








  6.922.65 0.750.44 7.721.72 3.740.21 
      
 
 
Table 1 : Deuterium-labeled fumarate, malate and water concentrations measured in 
tissue extracts using 2H NMR.  The concentrations of the protonated species in 
tumors were measure, using 1H NMR.  For malate this was based on the upfield 2H 
and 1H resonances at 2.4 ppm since the downfield resonance was not resolved from 
the water resonance. The concentrations were measured in the indicated tissues 20 
minutes after i.v. injection of [2,3-2H2]fumarate.  The measurements in tumor, kidney, 
liver and skeletal muscle were made in EL4 tumor-bearing mice, which were either 
etoposide (67 mg/kg) or vehicle-treated (Control).   The measurements in heart 
muscle were made in non-tumor bearing mice and extracts were made before (0) 
and at the indicated  times after [2,3-2H2]fumarate injection.  Data are expressed as 












 20 min 70 min 
 BT AT BT AT 
[2,3-
2
H2]fumarate 12.353.61 10.080.89 4.951.43 4.450.50 
[2,3-
2
H2]malate 0.030.01 0.470.05 0.0040.003 0.190.09 
HDO 20.161.14 19.321.68 22.681.42 23.521.21 
 
Table 2:  Deuterium-labeled fumarate and malate concentrations in the blood of EL4 
tumor-bearing mice before (BT) and after (AT) etoposide-treatment. Blood was 
collected by cardiac puncture at the specified times after i.v. injection of 1 g/kg [2,3-
2H2]fumarate and the concentrations measured using 
2H NMR. Data are expressed 










H2]malate [mM] HDO [mM] 
5 7.45 ± 0.39 0.04 ± 0.03 11.73 ± 0.28 
60 5.35 ± 0.89 0.25 ± 0.05 11.91 ± 0.50 
 
Table 3:  Deuterium-labeled fumarate, malate and water concentrations measured in 
mouse erythrocyte suspensions using 2H NMR. The concentrations were measured 
at the indicated time points after the addition of 8 mM [2,3-2H2]fumarate. Data are 







Figure 1: (A-D) 2H NMR spectra of murine lymphoma (EL4) cell culture medium. (A) 
Medium from untreated cells and (B) cells treated for 24 h with 15 M etoposide, 1 
minute after the addition of 5 mM [2,3-2H2]fumarate. (C) Medium from untreated cells 
and (D) cells treated for 24 h with etoposide, 2 h after the addition of [2,3-
2H2]fumarate. (E-F) Deuterated fumarate, malate and water concentrations in 
medium from untreated (E) and etoposide-treated cells at the indicated times after 
addition of 5 mM [2,3-2H2]fumarate (F). Rate of malate production in untreated and 
etoposide-treated EL4 cell suspensions (**P=0.0018) (±SD, n=3 biological 
replicates) (G). (H-M) Production of labeled malate and water in cultures of human 
colorectal (Colo205) and breast cancer (MDA-MB-231) cells following the addition of 
5 mM [2,3-2H2]fumarate.  Deuterated fumarate, malate and water concentrations in 
medium from untreated (H,K) and cells treated for 24 h with MEDI3039 (I,L), at the 
indicated times after the addition of 5 mM [2,3-2H2]fumarate. (J,M) Rate of labeled 
malate production in untreated and MEDI3039-treated Colo205 (***P=0.008) (J) and 
MDA-MB-231 (****P<0.0001) cells (Data are presented as mean ±SD, n=3 biological 
replicates) (M).  
Figure 2: 2H MR spectroscopic measurements of labeled fumarate, malate and 
water concentrations in EL4 (A - E), MDA-MB-231 (F - J) and Colo205 (K - O) 
tumors.  Tumor spectra were acquired before and 48 h after etoposide treatment (67 
mg/kg) of EL4 tumor-bearing mice (n=3,**P < 0.01, ****P <0.0001 and before and 24 
h after treatment of MDA-MB-231 (n=5, *P < 0.05, **P < 0.01, ***P <0.001) and 
Colo205 tumor-bearing mice (n=5, ***P <0.001, ****P <0.0001) with MEDI3039 (0.8 
mg/kg).  (B, D, G, I, L, N). Sum of 12 2H spectra recorded over 60 minutes. The [2,3-
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2H2] fumarate injection (1 g/kg) started 5 min after the start of acquisition of the first 
spectrum. The peaks were fitted individually using prior knowledge. (E,J,O)  
Estimated tumor malate concentrations pre- and post-treatment at indicated time 
points after [2,3-2H2] fumarate injection. (*P < 0.05, **P < 0.01, ***P <0.001, ****P 
<0.0001). Data are shown as mean ± SD. 
Figure 3: Malate/fumarate and malate/water signal ratios in EL4, MDA-MB-231 and 
Colo205 tumors before and after treatment. (A) Tumor [2,3-2H2]malate/[2,3-
2H2]fumarate and (B) [2,3-
2H2]malate/semi heavy water (HDO) ratios, obtained by 
summing the fumarate, malate and HOD signals over 65 minutes after injection of 
[2,3-2H2]fumarate, before treatment and at 48 hours after treatment of EL4 tumor-
bearing mice with etoposide (67 mg/kg) (n=3, *P < 0.05, **P < 0.01). Data are 
presented as mean ± SD. (C) [2,3-2H2]malate/[2,3-
2H2]fumarate and (D) [2,3-
2H2]malate/semi heavy water (HDO) ratios before and at 24 h after treatment of 
MDA-MB-231 tumor-bearing mice with MEDI3039 (0.8 mg/kg) (n=5, **P < 0.01).  (E) 
[2,3-2H2]malate/[2,3-
2H2]fumarate ratio and (F) [2,3-
2H2]malate/semi heavy water 
(HDO) ratios before and at 24 h after treatment of Colo205 tumor-bearing mice with 
MEDI3039 (0.8 mg/kg) (n=5, **P < 0.01, *** P <0.001).  Data are shown as box and 
whisker plots.   
 
Figure 4:  Fumarase activity in the EL4, Colo205 and MDA-MB-231 cells (A) and 
tumors (B) following treatment with the indicated drug concentrations.   Western blot 
analysis of fumarase expression in EL4 (C), Colo205 (D) and MDA-MB-231 (E) 
tumors following treatment with the indicated drug concentrations. Densitometric 
analysis of the western blots. Fumarase band intensities relative to those of GAPDH 
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(three biological replicates, data are presented as mean  S.E.M., *P < 0.05, **P < 
0.01, ***P < 0.001). 
 
 
Figure 5:  Volumes of (A) EL4, (B) MDA-MB-231 and (C) Colo205 tumors before 
and 48 h after etoposide treatment (EL4) or 24 h after MEDI3039 treatment (MDA-
MB-231, Colo205) (n=5, data are presented as mean  SD, ****P < 0.0001)  D) ATP 
concentrations measured in tumor extracts before (n=5) and after (n=5) treatment, 
data are presented as mean  SD, **P < 0.01, ***P < 0.001. 
 
Figure 6: Histological assessment of tumor cell death following treatment. Tumor 
sections were stained for CC3 and TUNEL (n=5 per group, drug- and vehicle-
treated.) CC3 (A,B) and TUNEL (D,E) staining of EL4 tumor sections taken 48 h 
after treatment of the animals with etoposide or drug vehicle (control). CC3 
(G,H,M,N) and TUNEL (J,K,P,Q) staining of MDA-MB-231 and Colo205 tumor 
sections taken 24 hours after treatment of the animals with MEDI3039 (0.8 mg/kg) or 
drug vehicle (control). ****P < 0.0001. 
 
Figure 7: Metabolite concentration maps in the central slice derived from dynamic 
3D CSI images summed over the first 30 minutes of signal acquisition following [2,3-
2H2]fumarate injection into EL4 tumor-bearing mice. The color code represents 
concentration (in mM) derived from the ratios of the peak intensities in the malate 
and fumarate maps to peak intensities in an initial HDO map and corrected for the 
number of 
2
H labels per molecule and signal saturation. (A-D) The locations of the 
tumors are outlined by dotted white lines. Approximate concentration maps of (A) 
 33 
fumarate pre-treatment; (B) malate pre-treatment; (C) fumarate 48 h post-treatment; 
(D) malate 48 h post-treatment. 
 
 







